« Return to News | R&D Trends | Study Conduct

University of Cambridge opens pancreatic cancer research center

Tuesday, March 29, 2011 01:09 PM

The University of Cambridge, U.K., has opened the Cambridge Pancreatic Cancer Center, a multi-disciplinary center focusing on pancreatic research.

The center aims to provide treatment and diagnostic options to local and international pancreatic cancer patients seeking novel treatments, and to design and implement ways to increase patient participation in pancreatic cancer trials locally, nationally and internationally.  The center is also working to establish a multi-disciplinary research community within the University of Cambridge that coordinates and sponsors research projects to develop new diagnostic and therapeutic approaches for pancreatic cancer and contribute to publications in pancreatic cancer medicine for broad dissemination to government, academia and industry. 

Harpal Kumar, chief executive of Cancer Research U.K., said, "This new center in Cambridge will give patients access to trials of exciting new treatments where they otherwise may not have many options. The involvement of Cancer Research U.K.'s leading scientists will ensure that discoveries made in the lab reach these patients as fast as possible."

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.